$APRE

Aprea Therapeutics, Inc. (APRE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 apre-20260812xex99d1.htm EX-99.1 ​ Exhibit 99.1 ​ Aprea Therapeutics Announces Second Quarter 2026 Financial Results ​ Enrollment in the ongoing Phase 1 dose escalation ACESOT-1051 trial of oral WEE1 inhibitor APR-1051 is accelerating as dose escalation advances Aprea p

Aprea Therapeutics, Inc. (APRE) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001781983 0001781983 2026-06-16 2026-06-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 16, 2026

Aprea Therapeutics has filed a notice for the resale of up to 5.5 million shares by its selling stockholders. This information comes from a recent SEC filing. The company's stock symbol is APRE.

Aprea Therapeutics (NASDAQ: APRE) has registered 74,349,426 shares of Common Stock for resale by selling stockholders. This registration covers shares issuable upon the exercise of both pre-funded warrants (37,174,713 shares) and common warrants (37,174,713 shares) that were issued in a private placement on March 31, 2026. Aprea Therapeutics will not receive proceeds from the resales themselves but will receive cash if the outstanding warrants are exercised, with proceeds intended for clinical trials, working capital, and general corporate purposes.

Aprea Therapeutics announced that its abstract detailing early results from the first-in-human Phase 1 ACESOT-1051 study of the WEE1 inhibitor APR-1051 for advanced solid tumors has been accepted for presentation at the ASCO 2026 Annual Meeting. The presentation will be a poster session on May 30, 2026, featuring initial safety and activity findings. This marks a significant clinical milestone, with investors closely watching for efficacy, safety, and biomarker data.

Aprea Therapeutics has secured approximately $30 million in gross proceeds through an oversubscribed private placement, extending its cash runway into Q1 2028. The company also reported positive clinical data from its Phase 1 ACESOT-1051 trial for WEE1 inhibitor APR-1051, showing a confirmed partial response in PPP2R1A-mutated endometrial cancer and generally manageable safety. This financing and promising trial data reinforce Aprea's commitment to developing targeted therapies for biomarker-defined cancers.

Aprea Therapeutics (APRE) has shown early clinical proof-of-concept for APR-1051 in endometrial cancer and strengthened its financial position by raising $8.7 million. The company has narrowed its operating losses year-over-year, and its cash runway is projected to extend into Q1 2027. Further clinical updates are anticipated in Q2 2026, positioning the company for key milestones.

Aprea Therapeutics (NASDAQ:APRE) reported its Q4 earnings, revealing an EPS of $(0.32), which missed the analyst estimate of $(0.30). The company's sales for the quarter were $3.337K, significantly down from $205.817K in the prior year. This headline-only article highlights the key financial discrepancies for the pharmaceutical company.

DOYLESTOWN, Pa., Oct. 24, 2025 ( GLOBE NEWSWIRE ) -- Aprea Therapeutics, Inc. ( Nasdaq: APRE ) ( "Aprea", or the "Company" ) , a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, ...

DOYLESTOWN, Pa., Aug. 28, 2025 ( GLOBE NEWSWIRE ) -- Aprea Therapeutics, Inc. APRE ( "Aprea", or the "Company" ) , a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, today ...